News - Page 2 of 13 - Leukaemia Care

25th July 2024

NEW oral treatment for ALL patients approved in Scotland

Leukaemia Care are pleased to announce that adult patients with philadelphia chromosome–positive (Ph+) acute lymphoblastic leukaemia (ALL) now have access to Dasatinib thanks to the decision made by the National Cancer Medicines Advisory Group (NCMAG) today.

3rd July 2024

Tribute to Dr Richard Taylor President of Leukaemia Care

We recently heard the sad news about the passing of Dr Richard Taylor. Here we share how he supported Leukaemia Care for over 15 years.

17th May 2024

Research updates from the American Society of Hematology (ASH) conference

Explore the latest highlights from the 2023 American Society of Hematology (ASH) conference, offering valuable insights into recent studies and developments.

9th May 2024

NEW oral treatment for AML patients approved in Scotland, England and Wales

Leukaemia Care is pleased to announce that newly diagnosed acute myeloid leukaemia (AML) patients with an IDH1 mutation now have access to ivosidenib with azacitidine thanks to a decision made by the National Institute for Health and Care Excellence (NICE) today.

8th May 2024

Leukaemia Care launches 2024 manifesto

Leukaemia Care launches manifesto calling for improved early diagnosis rates and for leukaemia patients to receive the best possible care and support throughout their cancer journey.

2nd May 2024

Leukaemia Care supports ITV’s Emmerdale storyline

Over the last few months, Leukaemia Care has been working closely with the writers of the popular ITV soap Emmerdale, focusing on characters Dawn and Billy as they navigate their baby Evan’s acute lymphoblastic leukaemia (ALL) diagnosis.

23rd April 2024

Sick pay and cancer – are you counting the cost?

New briefing lifts the lid on the financial difficulty working people face when their sick pay doesn’t pay the bills. 

11th April 2024

Approval for the first CAR-T treatment for ALL is renewed

CAR-T therapy, tisagenlecleucel, has been given long term approval to be used on the NHS in England, thanks to a decision made by the National Institute for Health and Care Excellence's (NICE).

11th March 2024

NEW oral treatment for AML patients approved in Scotland

Leukaemia Care are pleased to announce that newly diagnosed acute myeloid leukaemia (AML) patient with an IDH1 mutation who are ineligible for standard induction chemotherapy now have access to ivosidenib with azacitidine thanks to the decision made by the Scottish Medicines Consortium (SMC) today.

5th March 2024

Leukaemia Care, national Leukaemia Charity, appoints new CEO

The Board of Trustees for Leukaemia Care is pleased to announce the appointment of Colin Dyer as the new Chief Executive of Leukaemia Care.